GE HealthCare vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GE HealthCare Technologies Inc. (GEHC)

Q3 20268 Jul – 6 Oct 2026

▲2▼2

GEHC Q3: Strong Orders and Deals Offset by CFO Exit and Recall

Record orders and backlog GE HealthCare beat Q2 estimates with 11% organic order growth and a record $23.9 billion backlog, signaling strong future revenue. A $500 million Catholic Health deal also boosted confidence.
This shows robust demand and a healthy pipeline, a key positive driver for the stock.
New product approvals and dividend hike The company received European CE Mark for its photon-counting CT scanner and raised its dividend by 14%. It is also in advanced talks to buy Sofie Biosciences for about $1 billion.
These events highlight innovation and shareholder returns, supporting the stock price.
CFO departure and fraud investigation The CFO left the company, and a securities-fraud investigation tied to the April Q1 earnings miss is ongoing. This raises concerns about management stability and financial reporting.
Leadership turnover and legal issues can undermine investor trust and weigh on the stock.
Product recall and segment weakness A Class II recall of Centricity PACS software affected 1,443 systems due to wrong-patient data risk. Patient Care Solutions revenue fell 13.3%, and the stock is down 14.2% year to date.
Recall and revenue decline are operational setbacks that pressure the stock price.

September 20265 Aug – 6 Oct 2026

▲3

GEHC's record orders, Europe CT clearance, $1B Sofie deal, dividend hike offset by software recall

Record $23.9B backlog on 11.1% order growth Q2 organic orders rose 11.1% with a record $23.9B backlog and 1.15x book-to-bill, and 85% of Q3 equipment revenue already secured. Strong future demand supports revenue visibility, though Patient Care Solutions revenue fell 13.3% with negative segment profit.
This is the core demand signal that drives GEHC's revenue outlook and investor confidence.
Photonova Spectra CT gets CE Mark for Europe GEHC's photon-counting CT system won CE Mark, opening European sales in a market growing 29.4% a year. This expands the commercial opportunity for a high-end imaging product, though the stock slipped 1.1% after the news and remains down 14.2% year to date.
New product approval expands GEHC's addressable market and future revenue potential.
Advanced talks to buy Sofie Biosciences for ~$1B GEHC is in advanced talks to acquire Sofie Biosciences for about $1 billion, adding radiopharmaceuticals and PET imaging agents. This would strengthen its pharmaceutical diagnostics business, though the deal could still fall apart and uses cash for growth.
A major acquisition would expand GEHC's diagnostics pipeline and is a key strategic catalyst.
Dividend raised 14%, but Centricity PACS recall GEHC raised its quarterly dividend 14% to $0.04 and added a finance leader to its board, signaling confidence. But a voluntary Class II recall of Centricity PACS software across 1,443 systems over wrong-patient data risk could mean remediation costs and reputational damage.
The dividend hike is a positive capital signal, while the recall is a real regulatory and operational counterweight.

Latest5 Aug – 6 Oct 2026

▲3

GEHC's record orders, Europe CT clearance, $1B Sofie deal, dividend hike offset by software recall

Record $23.9B backlog on 11.1% order growth Q2 organic orders rose 11.1% with a record $23.9B backlog and 1.15x book-to-bill, and 85% of Q3 equipment revenue already secured. Strong future demand supports revenue visibility, though Patient Care Solutions revenue fell 13.3% with negative segment profit.
This is the core demand signal that drives GEHC's revenue outlook and investor confidence.
Photonova Spectra CT gets CE Mark for Europe GEHC's photon-counting CT system won CE Mark, opening European sales in a market growing 29.4% a year. This expands the commercial opportunity for a high-end imaging product, though the stock slipped 1.1% after the news and remains down 14.2% year to date.
New product approval expands GEHC's addressable market and future revenue potential.
Advanced talks to buy Sofie Biosciences for ~$1B GEHC is in advanced talks to acquire Sofie Biosciences for about $1 billion, adding radiopharmaceuticals and PET imaging agents. This would strengthen its pharmaceutical diagnostics business, though the deal could still fall apart and uses cash for growth.
A major acquisition would expand GEHC's diagnostics pipeline and is a key strategic catalyst.
Dividend raised 14%, but Centricity PACS recall GEHC raised its quarterly dividend 14% to $0.04 and added a finance leader to its board, signaling confidence. But a voluntary Class II recall of Centricity PACS software across 1,443 systems over wrong-patient data risk could mean remediation costs and reputational damage.
The dividend hike is a positive capital signal, while the recall is a real regulatory and operational counterweight.

July 20268 Jul – 30 Jul 2026

▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.
The Q2 earnings beat is the main new event driving the stock this period.
$500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.
A major new contract that directly boosts future revenue and investor confidence.
CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.
New negative developments that create uncertainty and could pressure the stock.
Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.
A new collaboration that showcases GEHC's technology and potential for future growth.

8 Jul – 30 Jul 2026

▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.
The Q2 earnings beat is the main new event driving the stock this period.
$500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.
A major new contract that directly boosts future revenue and investor confidence.
CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.
New negative developments that create uncertainty and could pressure the stock.
Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.
A new collaboration that showcases GEHC's technology and potential for future growth.

Q2 202617 Jun – 30 Jun 2026

▲3▼1

GEHC's AI product wins offset by weak profit guidance

Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.
This is the biggest new event of the period and directly explains the stock's drop.
FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.
A new regulatory approval expands the product portfolio and is a fresh positive catalyst.
RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.
A new analyst rating is a fresh event that directly lifted the stock on the day.
AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.
Shows the company's long-term growth potential in AI, a key theme for future earnings.

June 202617 Jun – 30 Jun 2026

▲3▼1

GEHC's AI product wins offset by weak profit guidance

Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.
This is the biggest new event of the period and directly explains the stock's drop.
FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.
A new regulatory approval expands the product portfolio and is a fresh positive catalyst.
RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.
A new analyst rating is a fresh event that directly lifted the stock on the day.
AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.
Shows the company's long-term growth potential in AI, a key theme for future earnings.

17 Jun – 30 Jun 2026

▲3▼1

GEHC's AI product wins offset by weak profit guidance

Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.
This is the biggest new event of the period and directly explains the stock's drop.
FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.
A new regulatory approval expands the product portfolio and is a fresh positive catalyst.
RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.
A new analyst rating is a fresh event that directly lifted the stock on the day.
AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.
Shows the company's long-term growth potential in AI, a key theme for future earnings.

Agilent Technologies Inc (A)

Q3 20269 Jul – 29 Sep 2026

▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.
This is the main new financial event that directly boosted the stock in August.
China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.
These are new geographic and customer wins that expand Agilent's revenue base.
Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.
New product approvals are concrete growth catalysts for the diagnostics segment.
AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.
This captures both the positive long-term drivers and the real risks that could limit upside.

August 20269 Jul – 29 Sep 2026

▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.
This is the main new financial event that directly boosted the stock in August.
China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.
These are new geographic and customer wins that expand Agilent's revenue base.
Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.
New product approvals are concrete growth catalysts for the diagnostics segment.
AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.
This captures both the positive long-term drivers and the real risks that could limit upside.

Latest13 Jul – 29 Sep 2026

▲4

Agilent's Q3 beat and China/reshoring momentum drive shares higher

Q3 earnings beat and raised guidance Agilent beat Q3 estimates with non-GAAP EPS up 18% and raised full-year guidance, sending shares up 9.6% since the report. Broad demand across pharma and China, plus Advanced Therapeutics up nearly 30%, shows the core business is accelerating and supports a higher stock price.
This is the biggest new positive catalyst this period, directly driving the stock higher.
China strength and reshoring orders Management said China delivered double-digit growth in pharma and food and high-teens in advanced materials, and Agilent booked its first reshoring orders from five top-10 pharma companies. This opens a new demand source and supports long-term growth, pushing the stock up.
New geographic and reshoring demand drivers that were not previously reported and directly boost growth outlook.
Instrument replacement cycle and lab automation Agilent is less than halfway through its liquid chromatography replacement cycle, worth 200-300 basis points of growth, and about a quarter through gas chromatography, worth 100 basis points. These multi-year upgrades plus lab automation provide a steady tailwind for revenue and the stock.
New details on replacement cycles and automation that underpin future growth, not previously reported.
New AI product launches and investment Agilent launched a Gen5 AI cell identification module for BioTek imagers and led a multimillion-dollar investment in HALO X-ray Technologies. These moves expand its AI and security screening offerings, signaling innovation that can drive future sales and support the stock.
New product and investment news that shows Agilent is advancing technology, a positive for future growth.

9 Jul – 26 Aug 2026

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.
New product and guidance signal future growth, a key driver for the stock.
FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.
Regulatory wins open new markets and deepen partnerships, directly boosting future sales.
Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.
Guidance raise and China recovery are the biggest new fundamental drivers for the stock.
Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.
Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 202620 Jun – 26 Jun 2026

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.
This is the core financial result that directly drives the stock and shows the company's health.
Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.
This is a major strategic move that directly affects future growth and profitability.
China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.
It shows Agilent investing in future technologies and markets, which can drive growth.
Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.
It highlights a favorable industry trend that supports Agilent's revenue growth.

June 202620 Jun – 26 Jun 2026

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.
This is the core financial result that directly drives the stock and shows the company's health.
Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.
This is a major strategic move that directly affects future growth and profitability.
China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.
It shows Agilent investing in future technologies and markets, which can drive growth.
Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.
It highlights a favorable industry trend that supports Agilent's revenue growth.

20 Jun – 26 Jun 2026

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.
This is the core financial result that directly drives the stock and shows the company's health.
Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.
This is a major strategic move that directly affects future growth and profitability.
China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.
It shows Agilent investing in future technologies and markets, which can drive growth.
Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.
It highlights a favorable industry trend that supports Agilent's revenue growth.